secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001213900-25-108722
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX Q3 net loss $9.2M; cash $8.1M; FDA feedback for BX011 and BX004 positive
------------------------------------------------------------------------------

- Net loss of $9.2M in Q3 2025 vs net income of $9.6M in Q3 2024 due to warrant fair value changes.
- Cash and restricted cash $8.1M as of Sep 30, 2025, from $18M at Dec 31, 2024; runway into Q1 2026.
- R&D expenses $6.1M, G&A $2.4M; net cash used in operations $22.0M for nine months vs $30.7M in 2024.
- FDA provided positive feedback on BX011 clinical pathway for S. aureus diabetic foot infections; Phase 2a planned.
- BX004 clinical hold feedback imminent; Phase 2b topline results expected Q1 2026; FDA outlined potential Phase 3 pathways.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025108722/0001213900-25-108722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025108722/ea0265281-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-108722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer